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Abstract
Background: Although the exact etiology of obsessive-compulsive disorder (OCD) is unknown, there is growing
evidence of a role for immune dysregulation in the pathophysiology of the disease, especially in the innate immune
system including the microglia. To test this hypothesis, we studied inflammatory markers in monocytes from pediatric
patients with OCD and from healthy controls.
Methods: We determined the percentages of total monocytes, CD16+ monocytes, and classical (CD14highCD16−),
intermediate (CD14highCD16low), and non-classical (CD14lowCD16high) monocyte subsets in 102 patients with
early-onset OCD and in 47 healthy controls. Moreover, proinflammatory cytokine production (GM-CSF, IL-1β,
IL-6, IL-8, and TNF-α) was measured by multiplex Luminex analysis in isolated monocyte cultures, in basal
conditions, after exposure to lipopolysaccharide (LPS) to stimulate immune response or after exposure to LPS
and the immunosuppressant dexamethasone.
Results: OCD patients had significantly higher percentages of total monocytes and CD16+ monocytes than healthy
controls, mainly due to an increase in the intermediate subset but also in the non-classical monocytes. Monocytes
from OCD patients released higher amounts of GM-CSF, IL-1β, IL-6, IL-8, and TNF-α than healthy controls after exposure
to LPS. However, there were no significant differences in basal cytokine production or the sensitivity of monocytes to
dexamethasone treatment between both groups. Based on monocyte subset distribution and cytokine production
after LPS stimulation, patients receiving psychoactive medications seem to have an intermediate inflammatory profile,
that is, lower than non-medicated OCD individuals and higher than healthy controls.
Conclusions: These results strongly support the involvement of an enhanced proinflammatory innate immune
response in the etiopathogenesis of early-onset OCD.
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Background
Obsessive-compulsive disorder (OCD) is a neuropsychi-
atric disease characterized by recurrent obsessions and/
or compulsions that are distressing, time-consuming, or
significantly impairing [1]. It is the fourth most common
psychiatric illness, with a lifetime prevalence of 1–3%
[2]. OCD presents a bimodal distribution for age at
onset with a peak at 12–14 years (early-onset) and
another at 20–22 years (late-onset). Indeed, in 30–50%
of patients, obsessive-compulsive symptoms start to
develop in childhood [3, 4]. It has been proposed that
childhood-onset OCD may be a distinct form of the dis-
order with different etiopathogenic mechanisms [4, 5].
Evidence from different lines of research suggest a
possible role of immune dysregulation in the pathophysi-
ology of OCD [6–8]. The hypothesis of immune dysreg-
ulation in OCD was originally based on the association
found between streptococcal infections and the abrupt
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onset of obsessive-compulsive symptoms. In this regard,
Swedo et al. reported an increased frequency of obsessive-
compulsive symptoms and OCD in children with Sydenham’s
chorea (SC), a delayed neurological complication following
streptococcal infections [9]. The syndrome was named
Pediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcal Infections (PANDAS), a
subset of childhood tic disorder and/or OCD which
may be causally related to group Aβ-hemolytic streptococ-
cal infection [10, 11].These findings were confirmed in
subsequent studies [12, 13] and were also extended to pa-
tients with a past streptococcal infection without SC
symptoms [7, 14]. Although there is some controversy, it
has been hypothesized that this phenomenon may be due
to the production of antibodies against basal ganglia struc-
tures [6, 7, 11]. In addition to streptococcus infection,
other infectious diseases including Borrelia burgdorferi,
mycoplasma, Toxoplasma gondii, or Borna disease virus
have been associated with OCD [7, 15]. As different etio-
logic factors, both infectious and non-infectious, may be
involved, the term PANDAS evolved later to a more wide
spectrum of acute neuropsychiatric syndrome named
PANS (pediatric acute-onset neuropsychiatric syndrome)
[15]. These findings have led to increased interest in the
involvement of immunological mechanisms in the etio-
pathogenesis of OCD, regardless of whether it fulfills the
diagnostic criteria for PANDAS or not. Some studies have
suggested a dysregulation of the immune function in
OCD based on alterations in innate and adaptive
immune-related parameters such as proinflammatory
cytokine levels [16–18], antineural antibodies [8, 19, 20],
or hypothalamus-pituitary-adrenal axis dysregulation
[21, 22]. However, the results to date are inconclusive.
Several lines of evidence suggest that dysfunction of
innate immunity, including the microglia, the brain’s
resident immune cells derived from the monocyte
lineage, may occur in a number of neuropsychiatric
conditions [23–26]. The innate immune system has a
pivotal role in initiating, directing, and prolonging the
immune response. The main immune cells involved in
innate response are monocytes, which circulate in the
blood, promote rapid responses, and orchestrate inflamma-
tion through the release of proinflammatory cytokines [27].
In addition, this system participates in neuroprotection and
neurodevelopment [28]. Human blood monocytes are a
heterogeneous population that can be segregated into three
functionally different subsets based on their expression of
CD14 and CD16: classical (CD14highCD16−), intermediate
(CD14highCD16low), and non-classical (CD14lowCD16high)
monocytes [29]. CD16+ monocytes (including intermediate
and non-classical monocytes [30]) and specifically inter-
mediate monocytes have been termed “proinflammatory”
based on their higher production of inflammatory cytokines
such as interleukin 6 (IL-6), IL-1β, and tumor necrosis
factor alpha (TNF-α) and because of the expansion of these
cells in infections and inflammatory diseases [30, 31].
However, the particular state of these cells in OCD is
not well known.
Hence, to improve our understanding of the potential
role of the innate immune dysregulation in early-onset
OCD, we aimed (1) to characterize the monocyte subsets
in pediatric patients with OCD and healthy controls, (2)
to examine the functionality of cultured monocytes by
measuring proinflammatory cytokine and chemokine
production after exposure to immune regulators in both
OCD and controls, and (3) to explore the relationship of




One hundred and two children and adolescents aged
between 8 and 19 years with a current diagnosis of
obsessive-compulsive disorder (OCD) according to DSM-
IV [32] criteria were recruited from the Department of
Child and Adolescent Psychiatry and Psychology at the
Hospital Clínic in Barcelona. The Spanish version [33] of
the semi-structured diagnostic interview K-SADS-PL
(Schedule for Affective Disorders and Schizophrenia for
School-Age Children-Present and Lifetime Version) [34]
was administered with both parents and the child as in-
formant in order to establish the diagnosis of OCD and to
assess past and current psychiatric comorbidity. Patients
with psychiatric comorbidities other than OCD were not
excluded. In addition, due to the naturalistic design of the
study, we allowed the inclusion of patients receiving
psychoactive medications. Exclusion criteria included
intellectual disability, neurological disorders, and known
inflammatory disease. The age of onset of OCD was
defined as the age at which patients first displayed signifi-
cant distress or impairment associated with obsessive-
compulsive symptoms. OCD severity was measured at the
time of admission using the Children’s Yale-Brown
Obsessive-Compulsive Scale (CY-BOCS) [35], whose max-
imum score is 40 points.
Forty-seven healthy controls (age range 11–18 years)
were recruited from schools in the same geographical
region. Controls and their parents were interviewed with
the Spanish version [33] of the K-SADS-PL to assess
current and past psychopathology. Subjects with a
personal history of psychiatric disorders, intellectual dis-
ability, and other neurological illness or known inflam-
matory disease were excluded.
All subjects were recruited between 2010 and 2014.
All participants denied the use of alcohol or other recre-
ational drugs during the semi-structured interview. All
procedures were approved by the hospital’s ethics com-
mittee. Written informed consent was obtained from all
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parents and verbal informed consent was given by all
subjects following an explanation of the procedures
involved.
Isolation of peripheral blood mononuclear cell (PBMC)
Blood samples of both OCD patients and healthy indi-
viduals were collected in BD Vacutainer tubes containing
acid citrate dextrose (Becton Dickinson, Franklin Lakes,
New Jersey, USA) for immune cell preparation. All
samples were taken during the morning, before 12 p.m.
Peripheral blood mononuclear cell (PBMC) suspensions
were prepared by density gradient centrifugation over
Ficoll-Plaque (GE Healthcare Bio-Science AB, Uppsala,
Sweden) at 750×g for 20 min at 18 °C. After washing the
interphase cells with phosphate-buffered saline (PBS),
PBMCs were frozen in fetal bovine serum (FBS) (Life
Technologies, Carlsbad, CA, USA) containing 10%
dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA)
and stored in liquid nitrogen until subsequent trials in
order to test patient and control immune cells in the
same series of experiments and thus to avoid batch
effects/interassay variation.
For subsequent analysis, cryopreserved PBMCs were
rapidly thawed and washed with RPMI 1640 supple-
mented with 2 mM L-glutamine, 10% FBS, 100 units/mL
penicillin, 100 μg/mL streptomycin (Life Technologies,
Carlsbad, CA, USA), and 50 units/mL Benzonase® nucle-
ase (Sigma-Aldrich, Saint Louis, MO, USA). Cells were
counted using an Ac·T diff™ automated analyzer (Beckman
Coulter, Miami, FL, USA).
Flow cytometric analysis
To investigate whether the composition of peripheral
monocytes is altered in early-onset OCD, a FACS-based
analysis was performed. For this purpose, an aliquot of
thawed PBMC containing at least 50,000 cells was
washed with PBS and stained with fixable viability dye
(eBioscience, San Diego, CA, USA) for 10 min at room
temperature, followed by surface staining for 20 min
with anti-HLA-DR-V500, anti-CD14-Pe-Cy7, and anti-
CD16-FITC antibodies (BD Pharmingen, San Diego, CA,
USA). After incubation, cells were analyzed by flow
cytometry on a BD FACSCanto II (BD Bioscience, San
Jose, CA, USA) using appropriate color compensation to
correct for spectral overlap and autofluorescence. Data
were analyzed with FlowJo version 10.1r5 software
(Ashland, OR, USA). The gating strategy for identifica-
tion of monocyte subsets is shown in Additional file 1:
Figure S1. Firstly, the putative monocyte population was
gated based on forward and side scatter profiles. Then,
after selecting viable cells, monocytes were discriminated
from the rest of leukocytes based on high expression of
HLA-DR. Finally, the different patterns of expression of
CD14 and CD16 allowed the identification of the three
monocyte subsets: classical (CD14highCD16−), intermedi-
ate (CD14highCD16low), and non-classical (CD14lowCD16-
high) monocytes. Isotype-matched control antibodies were
used to determine the cutoff between negative and
positive CD16. The combination of intermediate and non-
classical monocytes in a single population was considered
as CD16+ monocytes. Total monocytes were considered
as the sum of classical, intermediate, and non-classical
monocytes. Percentages of total monocytes, classical,
intermediate, and non-classical monocyte subsets, and all
CD16+ monocytes were assessed. Only samples with at
least 200 total monocytes were included in the statistical
analysis (91 early-onset OCD and 34 healthy controls).
Purification, culture, and stimulation of peripheral
monocytes
For the subsequent assessment of monocyte functional-
ity, monocytes were purified from PBMC by negative
selection using an indirect magnetic labeling system
(MACS, Miltenyi Biotec, Auburn, CA, USA) following
the manufacturer’s instructions. Briefly, non-monocytes,
such as T cells, NK cells, B cells, and dendritic cells,
were labeled using a cocktail of biotin-conjugated anti-
bodies and anti-biotin microbeads. These magnetically
labeled non-monocytes were depleted by being retained
on a MACS® Column in the magnetic field of a MACS
Separator while the unlabeled monocytes passed through
the column. This kit allowed the simultaneous enrich-
ment of classical, intermediate, and non-classical mono-
cytes. Purity of isolated monocytes was checked by flow
cytometry (routinely > 95). No monocytes were purified
from one sample from an OCD patient and one from a
healthy control, despite following the same protocol.
Purified monocytes (101 OCD patients and 46 con-
trols) were seeded at a density of 1.5 × 105 cells/well on
24-well plates and allowed to rest for 2 h in RPMI 1640
supplemented with 2 mM L-glutamine, 10% FBS,
100 units/mL penicillin, and 100 μg/mL streptomycin
(Life Technologies, Carlsbad, CA, USA) in a humidified
incubator with 5% CO2 at 37 °C prior to stimulation. To
characterize monocyte functionality, monocytes were
exposed to lipopolysaccharide (LPS), which is the major
component of the outer membrane of Gram-negative
bacteria, in order to stimulate the immune response, and
dexamethasone, a glucocorticoid known to have im-
munosuppressive properties, to test monocyte sensitivity
to immunoregulation. Hence, after resting for 2 h,
monocytes were preincubated for 30 min with or with-
out 100 nM dexamethasone followed by stimulation for
24 h with 1 ng/mL LPS (Sigma-Aldrich, Saint Louis,
MO, USA). LPS was dissolved in culture medium
whereas a stock solution of dexamethasone (1 mg/mL)
was prepared in ethanol and further diluted in culture
medium. Ethanol had no effect on monocyte cultures at
Rodríguez et al. Journal of Neuroinflammation  (2017) 14:261 Page 3 of 11
the concentration used in the experiment (final ratio of
1/25000). Hence, sterile culture medium was used as
negative control for all conditions. After 24 h of incuba-
tion, a supernatant was collected and cells were frozen.
Supernatants were stored at − 20 °C until subsequent
analysis.
Cytokine quantification in cell culture supernatant
For the analysis of monocyte functionality, inflammatory
cytokine levels in culture supernatants were measured in
basal conditions and after LPS or dexamethasone plus LPS
exposure of purified monocytes using multiplex bead-based
sandwich immunoassay with Luminex xMAP® technology
(Luminex, Austin, TX, USA). A commercially available 5-
plex panel including proinflammatory cytokines and
chemokines (IL-1β, IL-6, granulocyte-macrophage colony-
stimulating factor (GM-CSF), TNF-α, and IL-8) (cat no.
LHC0003, Invitrogen, Carlsbad, CA, USA) was used follow-
ing the manufacturer’s instructions. Briefly, supernatants
(25 μL) and standards were incubated with cytokine-
specific capture antibodies coupled to fluorescent beads.
Then, biotinylated detector antibodies were added, followed
by streptavidin-phycoerythrin incubation. All standards and
samples were analyzed in duplicate. Data were acquired
using Luminex 200 system and analyzed with xPonent v3.1
software (Luminex, Austin, TX, USA). Cytokine levels were
quantified using a five-parameter logistic regression curve
derived from the reference cytokine concentration stan-
dards supplied by the manufacturer. The sensitivity of the
assay allowed the detection of cytokine concentrations
within the following ranges: IL-1β 0.33–6800 pg/mL, IL-6
0.25–5000 pg/mL, GM-CSF 0.77–15,400 pg/mL, TNF-α
0.36–7300 pg/mL, IL-8 0.47–9500 pg/mL. For experimen-
tal data above the range of the standard curve, the values
were extrapolated, whereas samples below the lower limit
of quantitation were assigned a value of one half of the
minimum detection level for that cytokine as reported in
previous studies [36, 37]. For the vast majority of the cyto-
kines and assay conditions, at least 80% of the samples were
within the limits of quantification. For some samples, it was
not possible to determine cytokine concentration and so
the following numbers of samples were included in the
statistical analysis for each cytokine: IL-1β, 100 OCD and
43 controls; IL-6, 79 OCD and 39 controls; GM-CSF, 100
OCD and 44 controls; TNF-α, 98 OCD and 44 controls;
and IL-8, 79 OCD and 40 controls.
In order to assess inflammatory activation of peripheral
monocytes upon an immune challenge, percentages of
cytokine production with respect to untreated sample were
calculated for each cytokine level after treatment with LPS
alone or LPS plus dexamethasone. Besides, to estimate
monocyte sensitivity to dexamethasone, differences in cyto-
kine concentrations between LPS-treated and LPS +
dexamethasone-treated samples were computed and
expressed as percentages with respect to LPS stimulation.
Statistical analysis
Data were analyzed using IBM SPSS statistics 20 (IBM
Corp., Chicago, IL, USA). Normality was assessed using
Kolmogorov-Smirnov and Shapiro-Wilk tests. The
different immune parameters, including all percentages
of monocyte subsets and the five cytokine levels in basal
conditions and after LPS or LPS + dexamethasone treat-
ment, were found to follow a non-normal distribution.
Therefore, all variables were natural-log-transformed for
subsequent analysis. In order to test differences in socio-
demographic variables between patients and controls,
Student’s t test for continuous variables and chi-square
test for categorical variables were used. Pearson’s test
was also used to assess correlations. Univariate analyses
were performed adjusting for gender and age to assess
the difference in immune parameters between patients
and controls. When a significant correlation was identi-
fied between cytokine levels and monocyte subsets, the
corresponding monocyte subpopulation was introduced
as a covariate in the univariate analysis. When the
immune parameters were found to be associated with
OCD, we also assessed their putative relationship with
clinical variables such as disease severity, duration of
disease, or psychopharmacological status. When appropri-
ate, further pairwise comparison analyses were performed
using Bonferroni’s post hoc test.
All data are reported as means ± standard error of the
mean (SEM) of the original data, prior to log transform-
ation. All tests were two-tailed and significance level was
set at p < 0.05.
Results
Clinical and sociodemographic characteristics of the
sample
Demographic and clinical data of patients with OCD
and the control group are shown in Table 1. The mean
age was 14.78 years for OCD individuals and 16.29 years
for healthy controls (t = − 3.608, p = 0.0004). There were
52 boys (51%) and 50 girls (49%) in the case group and
14 boys (29.8%) and 33 (70.2%) girls among the controls
(χ2 = 5.86, p = 0.016). The mean symptom severity score
in OCD individuals, as assessed by the CY-BOCS scale
was 25.97 ± 0.64; this high value reflected the patho-
logical condition of patients. Some patients were also
diagnosed with internalizing disorders (anxiety or de-
pression disorders) (N = 46, 45.1%) or with neurodeve-
lopmental disorders (attention deficit hyperactivity
disorder (ADHD) or tics) (N = 22, 21.6%). However, the
presence of these comorbidities in some OCD patients
does not seem to have an effect on the frequency of
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monocyte subsets and cytokine levels, as no differences
were found between the groups (Additional file 2: Table S1).
Eighty-two patients (80.4%) received pharmacological
treatment with an antidepressant alone (N = 59, 72%), an
antidepressant combined with antipsychotic drugs (N =
22, 26.8%), or an antipsychotic alone (N = 1, 1.2%). The
most prescribed antidepressant was fluoxetine (in 45.7%
of patients receiving antidepressants), whereas the most
used antipsychotic was risperidone (in 43.5% of patients
taking antipsychotics). Ten patients were comedicated
with benzodiazepines (12.2%), four (4.9%) with long-
acting methylphenidate, and one (1.2%) with lithium
carbonate.
Although a different number of samples was included
in the analysis of monocyte subsets and the five proin-
flammatory cytokines, no differences were identified
between these populations regarding any of the clinical
and sociodemographic characteristics (data not shown).
Enrichment of CD16+ monocytes in peripheral blood of
OCD patients
OCD patients presented higher percentages of total mono-
cytes than healthy controls (F = 7.199, p = 0.008) (Fig. 1a).
Regarding different monocyte subsets, CD16+ monocytes
were enriched in OCD patients compared to healthy con-
trols (F = 18.188, p = 0.00004) (Fig. 1b). This effect was
Table 1 Demographic and clinical data of the study population
OCD patients (N = 102) Controls (N = 47) Statistic p value
Male gender, N (%) 52 (51.0) 14 (29.8) χ2 = 5.86 0.016a
Age (mean ± SEM) 14.78 ± 0.26 16.29 ± 0.26 t = − 3.608 0.0004b
Age of onset (mean ± SEM) 12.95 ± 0.28 – – –
Duration of illness, months (mean ± SEM) 24.62 ± 2.44 – – –
CY-BOCS score (mean ± SEM) 25.97 ± 0.64 – – –
Comorbidities, N (%)
Anxiety or mood disorders 46 (45.1) – – –
ADHD or tic disorder 22 (21.6) – – –
Treatment, N (%)
Medicated 82 (80.4) – – –
Antidepressants 59 (72) – – –
Antipsychotics 1 (1.2) – – –
Antidepressants + antipsychotics 22 (26.8) – – –
Non-medicated 20 (19.6) – – –




Fig. 1 Distribution of monocyte subsets in early-onset OCD patients (N= 91) and healthy controls (HC, N= 34). a Percentage of total monocytes in OCD
patients and healthy controls. b Percentage of all CD16+ monocytes, including CD14highCD16low and CD14lowCD16high monocytes, in OCD patients and
healthy controls. c Percentage of classical (CD14highCD16−), intermediate (CD14highCD16low), and non-classical (CD14lowCD16high) monocytes in OCD
patients and healthy controls. Results are expressed as means ± SEM of the original data, prior to log transformation. Statistical analysis was performed using
univariate general linear model adjusted for age and gender with natural-log-transformed data. **p< 0.01, ***p< 0.001, ****p< 0.0001
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largely driven by a twofold increase in intermediate mono-
cytes in OCD patients (F = 15.013, p = 0.0002) (Fig. 1c), al-
though non-classical monocytes were also slightly higher in
OCD individuals (F = 7.107, p = 0.009). Concurrently, clas-
sical monocytes were slightly less frequent in patients than
in controls (F = 10.188, p = 0.002) (Fig. 1c).
Higher production of inflammatory cytokines in OCD
patients
There was a high correlation between the levels of the five
different cytokines measured in the study (Additional file 3:
Table S2). In addition, cytokine levels were mainly signifi-
cantly correlated with total monocytes but not with the
different monocyte subsets (Additional file 4: Table S3).
No differences were identified in cytokine levels in basal
conditions between patients and controls (Additional file 5:
Table S4). Effects of monocyte stimulation with LPS or
LPS + dexamethasone are shown in Fig. 2. After LPS treat-
ment, OCD samples showed a significantly higher produc-
tion of inflammatory cytokines (IL-1β, F = 8.216 p = 0.005;
IL-6, F = 8.570 p = 0.004; GM-CSF, F = 4.433 p = 0.049;
TNF-α, F = 4.241 p = 0.041; IL-8, F = 6.330 p = 0.013) than
healthy controls. As expected, cells pretreated with dexa-
methasone before LPS stimulation released lower quan-
tities of inflammatory cytokines than those treated with
LPS alone in both OCD patients and controls. However,
cytokine levels after LPS + dexamethasone treatment were
still higher than in basal conditions. Due to cytokine pro-
duction after LPS stimulation, monocytes from OCD
patients released higher quantities of the inflammatory
cytokines than healthy controls after LPS + dexametha-
sone treatment. These differences were only significant for
some of the mediators: IL-1β (F = 5.528; p = 0.020), IL-6
(F = 6.284; p = 0.014), GM-CSF (F = 2.205; p = 0.140),
TNF-α (F = 1.576; p = 0.211), and IL-8 (F = 10.326; p =
0.002). Nevertheless, monocyte sensitivity to dexametha-
sone expressed as a percentage of reduction in cytokine
levels in LPS + dexamethasone-treated monocytes with
respect to LPS-stimulated cells did not differ between
patients and controls (Additional file 5: Table S4).
Clinical characteristics of OCD patients and immune
parameters
We also addressed the possible effects of pharmaco-
logical treatment on monocyte distribution and cytokine
production in cultured monocytes. We found a progres-
sive increase in CD16+ and intermediate and non-
classical subsets from healthy subjects to OCD individ-
uals receiving pharmacological treatment and finally to
non-treated patients (CD16+ monocytes F = 10.372, p =
0.00007; intermediate monocytes F = 8.647, p = 0.0003;
non-classical monocytes F = 3.561, p = 0.032) (Fig. 3a). In
contrast, the direction of this association was reversed
for classical monocytes, since the percentage of this sub-
set was higher in healthy individuals than in treated
patients and finally in unmedicated patients (F = 6.620,
p = 0.002) (Fig. 3a). The same pattern was identified for
cytokine levels after LPS stimulation: there was a
Fig. 2 Cytokine secretion by purified monocytes of early-onset OCD and healthy controls. Monocytes were cultured for 24 h with vehicle, lipopolysaccharide
(LPS) 1 ng/mL or pretreatment with dexamethasone (DEX) 100 nM for 30 min followed by addition of LPS 1 ng/mL. Cytokine secretion was assessed in culture
supernatants using Luminex xMAP Technology. Due to limitations of the immunoassay sensitivity, the sample sizes may vary for each cytokine: IL-1β, 100 OCD
and 43 controls; IL-6, 79 OCD and 39 controls; GM-CSF, 100 OCD and 44 controls; TNF-α, 98 OCD and 44 controls; and IL-8, 79 OCD and 40 controls. Results are
expressed as means ± SEM of the original data, prior to log transformation. Statistical analysis was performed using univariate general linear model adjusted for
age and gender with natural-log-transformed data.*p<0.05, **p<0.01
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progressive increase in cytokine concentrations from
healthy subjects to OCD patients receiving pharmaco-
logical treatment and finally to patients without medica-
tion. This association was significant for most cytokines
(IL-1β F = 5.464, p = 0.005; IL-6 F = 5.076, p = 0.008;
GM-CSF F = 1.917, p = 0.151; TNF-α F = 2.102, p =
0.126; and IL8 F = 4.526, p = 0.013, Fig. 3b). Post hoc
comparisons revealed that healthy controls had lower
levels of monocyte subsets and proinflammatory
cytokines compared to both untreated and treated OCD
patients (p < 0.05). However, no significant differences
were found between OCD individuals receiving psycho-
active medications and untreated patients.
In addition, we evaluated the putative relationship of
monocyte subset frequency and cytokine production
with severity of obsessive-compulsive symptoms as well
as with duration of disease. None of the immune param-
eters were significantly correlated with these clinical
variables (Additional file 6: Table S5).
Discussion
To our knowledge, this is the first study to evaluate the
distribution of peripheral monocyte subsets and to analyze
markers of monocyte activation and functionality in early-
onset OCD. Our results revealed a proinflammatory
predisposition of monocytes from OCD patients based on
the imbalance of monocyte subpopulations and their
over-reactivity to immune stimulation with LPS. More-
over, OCD patients receiving psychoactive medications
were found to have an intermediate inflammatory profile
compared to untreated patients and controls.
OCD patients showed an increase in the percentage of
total monocytes as well as in the CD16+ subset, especially
in intermediate monocytes but also in non-classical
monocytes, compared with healthy controls. Although
there is no previous evidence of an association between
altered monocyte frequencies and OCD, some authors
have identified high levels of monocytes in related disor-
ders like Tourette’s syndrome (TS) [38] or autism
spectrum disorder [39, 40]. However, no differences in the
monocyte subset distribution have been found [41].
Together with these alterations in monocyte subsets,
we found that isolated peripheral blood monocytes from
children with OCD behaved abnormally upon stimula-
tion with LPS, displaying excessive IL-1β, IL-6, GM-CSF,
TNF-α, and IL-8 production compared to monocytes
from healthy controls. Interestingly, we did not detect
any abnormal activation of monocytes from OCD
patients in basal conditions, but exposure to an immune
challenge was required for the over-reactivity of these
Fig. 3 Influence of medication on immune parameters in OCD. a Distribution of monocyte subsets (percentages of all CD16+, classical, intermediate, and
non-classical monocytes) in peripheral blood of medicated (N= 71) and non-medicated patients (N= 20) with early-onset OCD and healthy controls (HC,
N= 34). b Cytokine secretion by purified monocytes of medicated and non-medicated patients with early-onset OCD and healthy controls after 24 h of
stimulation with LPS 1 ng/mL (IL-1β 43 controls, 80 medicated OCD, 20 non-medicated OCD; IL-8 40 controls, 62 medicated OCD, 17 non-medicated OCD;
IL-6 39 controls, 66 medicated-OCD, 13 non-medicated OCD; GM-CSF 44 controls, 80 medicated OCD, 20 non-medicated OCD; TNF-α 44
controls, 79 medicated OCD, 19 non-medicated OCD). Results are expressed as means ± SEM of the original data, prior to log transformation. Statistical
analysis was performed using univariate general linear model adjusted for age and gender with natural-log-transformed data. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001
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cells. Whether this over-reactivity occurs upon other
types of immune stimulus such as psychological stress
remains to be elucidated. These findings are at odds with
results from previous studies with similar methodolo-
gies, which have reported either no differences or lower
production of several cytokines after LPS stimulation in
OCD individuals [42–45]. However, we should stress
that in these studies, the assessments involved different
types of samples including other immune cells and all of
them were conducted in adult patients, in whom the
pathological mechanism may be different [4, 5]. In
addition, cytokine production in children has been re-
ported to be different from that in adults [46, 47]. Apart
from the studies mentioned above, most authors have
investigated cytokine levels in serum or cerebrospinal
fluid in OCD [16–18, 47, 48] but the results were incon-
sistent due to methodological and sample differences
such as age, age at onset, disease duration, and pharma-
cological treatment. Interestingly, in our population,
monocytes from pediatric OCD patients were able to
respond to glucocorticoid exposure in the same way as
those from healthy individuals. However, due to the
over-reactivity of monocytes from OCD patients after
LPS stimulation, cytokine levels remained higher in
patients than in controls when treated with dexametha-
sone. The significant correlation identified between cyto-
kine levels and the percentage of total monocytes
indicates that those individuals with higher production
of inflammatory cytokines, both in basal conditions and
in response to stimulus, were also those with the higher
levels of monocytes and thus with a greater global in-
flammatory state. However, as all the samples were cul-
tured using the same amount of monocytes, we can rule
out that the amount of cytokines released was due to the
number of monocytes. In addition, as cytokine levels
were mainly not correlated with the different monocyte
subsets, the higher production of cytokines must be due
to a higher activation of monocytes rather than to
monocyte subset distribution.
This study also found that OCD patients receiving
pharmacological treatment seem to present an inter-
mediate inflammatory profile (including monocyte sub-
set distribution and cytokine production upon
stimulation with LPS) that is lower than non-medicated
OCD individuals and higher than healthy controls.
These results are in accordance with previous evidence
suggesting that treatment with antidepressant medica-
tions may have anti-inflammatory properties [49, 50].
However, post hoc analysis was not able to detect signifi-
cant differences between treated and untreated patients,
maybe due to the small size of the non-medicated group.
If the trend identified here is confirmed in subsequent
studies, the combined treatment with antidepressants
and anti-inflammatory drugs like glucocorticoids may be
a promising therapy for improving obsessive-compulsive
symptoms, as observed in patients with major depressive
disorder or schizophrenia [51, 52]. In addition, other
immune-modulating medications, such as anticytokine
agents, may be useful as adjunct therapy in OCD indi-
viduals, as observed in a patient with tumor necrosis
factor receptor-associated autoinflammatory syndrome
(TRAPS), in which psychiatric symptoms, including tics
and OCD, showed a remarkable improvement after
treatment with the IL-1 blocking agent anakinra [53].
Monocytes, which were found to be increased in OCD
patients in the present study, are the main cells impli-
cated in the first immune response upon infection.
Among the different monocyte subsets, CD16+ and
specifically the intermediate monocytes, which were
increased in our OCD population, are considered the
most inflammatory subpopulation due to their expres-
sion of inflammatory cytokines and other activation
markers and due to their expansion in infectious and
inflammatory diseases [29–31]. Circulating monocytes
can be recruited to the central nervous system (CNS)
upon exposure to psychosocial stress [25] or when
chronic or intense injury occurs in the brain, where they
contribute to the inflammatory response with their
phagocytic activity and the release of immune mediators
such as cytokines [28, 54]. Additionally, peripherally
produced cytokines secreted by monocytes, such as the
IL-1β, IL-6, GM-CSF, TNF-α, and IL-8 evaluated in this
study, not only act peripherally but also enter the CNS
where they increase neuroinflammatory responses and
affect neurotransmitter availability [55, 56], brain func-
tion, and neurodevelopment [57]. These effects occur
mainly in the basal ganglia and dorsal anterior cingulate
cortex [58], which have been implicated in the patho-
physiology of OCD [59]. Hence, monocyte activation
upon immune challenges and other potential stressors in
genetically susceptible individuals may be involved in
the onset, progression, and exacerbation of obsessive-
compulsive symptoms, as proposed for other psychiatric
diseases such as schizophrenia [23, 60], depression [58]
or anxiety [21]. This peripheral activation of monocytes
may also suggest microglial activation, since they are the
innate immune cells of the CNS. Although microglia
originate from myeloid precursors deriving from the
yolk sac during embryonic development, with minimal
contribution of bone marrow-derived progenitors in
adulthood [54, 61], monocytes and microglial cells may
exhibit similar responses to systemic stimuli [54, 62].
Activated microglia with a proinflammatory phenotype
are unable to remove debris and promote regeneration
of the inflamed tissue leading to a failure in immune
resolution and neuroprotection [28]. In addition, micro-
glial abnormalities may lead to alterations of synaptic
pruning as well as higher release of microglial-derived
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glutamate, which in turn might have neurotoxic effects
on dendrites and synapses [63]. Indeed, it has been
suggested that microglial dysregulation may have a role
in the pathophysiology of OCD and related diseases like
TS or autism. Postmortem studies evaluating gene
expression in basal ganglia from TS subjects identified
an increase in the expression of monocyte chemotactic
factor-1 (MCP-1) [64] and an upregulation of several
microglia-related genes [65], pointing to microglia prolif-
eration and activation. In addition, animal models such as
Hoxb8 knockout mice or L-histidine decarboxylase (Hdc)
knockout mice, exhibiting repetitive behaviors, mostly
grooming, have also suggested the participation of micro-
glia in the development of OCD and TS [63, 66, 67].
Taken together, our results indicate an enhanced
proinflammatory state in monocytes in early-onset OCD
characterized by alterations in monocyte subset distribu-
tion as well as higher production of inflammatory
cytokines after monocyte stimulation. It should be borne
in mind that our sample comprised OCD patients with a
variety of comorbidities and that most patients were re-
ceiving pharmacological treatment. However, the higher
activation state of monocytes from OCD patients identi-
fied here was not due to the presence of these condi-
tions. We should also stress the homogeneity of our
OCD sample in terms of age, age at onset, or duration
of disease, as all participants were children and adoles-
cents; this avoids the possible influence of these
confounding factors and allows the study of the specific
etiopathogenic mechanism underlying childhood-onset
OCD, which may differ from the pathophysiology of the
adult disorder [5]. In addition, a larger size of the
control sample, at least similar to that of the OCD
group, would be preferred. However, due to the frequent
difficulties found in the recruitment of healthy children
and adolescents, we were not able to include a higher
number of controls. Moreover, despite the imbalance in
gender between OCD patients and healthy controls and
the age difference between the groups, the results of the
univariate analysis adjusted for these two factors
revealed that the association between OCD and immune
parameters that was identified here was independent of
their potential confounding effect.
As we used a primary model of isolated monocytes,
the enhanced proinflammatory state in OCD patients
shown in this study was not influenced by the immune
response mediated by other immune cells. This means
that we can specifically determine the potential contri-
bution of monocyte lineage cells to the inflammatory
response in early-onset OCD. Nevertheless, although the
over-activation of monocytes found in the present study
was demonstrated by a number of parameters, only per-
ipheral activation markers were measured. Hence, even
though peripheral monocytes and circulating cytokines
are able to enter the brain [55] and although these
peripheral changes may also reflect microglial activation
[23], analysis of more inflammatory markers, including
central immune changes, is needed in order to understand
the complex inflammatory profile underlying OCD. In
addition to these limitations, it should also be borne in
mind that no adjustments for multiple comparisons were
applied due to the exploratory nature of the study and the
high correlation of the monocyte-derived products.
Hence, the results should be interpreted with caution.
Conclusions
In conclusion, the results of the present study point to a
proinflammatory state of monocytes from children and
adolescents with OCD. The enhanced activation of the
innate immune system may be triggered by exposure to
immunomodulatory stimuli like stress or infections lead-
ing to an increased production of cytokines that mediate
the inflammatory process. Further studies are necessary
to elucidate the role of innate immunity in the complex
pathophysiology of OCD and to understand the interplay
between neural and immune cells throughout the differ-
ent stages of development.
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